Sarepta partner Lysogene reports patient death in AAVance clinical trial

Lysogene (LYSGF) announced that a patient has passed away in the AAVance clinical trial, a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis Type IIIA, or MPS IIIA, also known as Sanfilippo syndrome type A.